The potential management of oral candidiasis using anti-biofilm therapies

Chanda, Warren; Joseph, Thomson Patrick; Wang, Wendong; Padhiar, Arshad Ahmed; Zhong, Ming-Chao

doi:10.1016/j.mehy.2017.06.029

Cited by 31 publications

(23 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, Candida spp. can overgrow under the condition of broad-spectrum antibiotics and immunosuppression (Chanda et al, 2017). However, microbial interactions, especially bacterial-fungal interactions, have not been extensively studied in asthma, and very little is known regarding the key/important microbial communities in the airway microbial interactions in asthma.…”

Section: Introductionmentioning

confidence: 99%

The Interactions of Airway Bacterial and Fungal Communities in Clinically Stable Asthma

Liu

Liang

et al. 2020

Front. Microbiol.

View full text Add to dashboard Cite

Dysbiotic airway microbiota play important roles in the inflammatory progression of asthma, and exploration of airway microbial interactions further elucidates asthma pathogenesis. However, little is known regarding the airway bacterial-fungal interactions in asthma patients. We conducted a cross-sectional survey of the sputum bacterial and fungal microbiota from 116 clinically stable asthma patients and 29 healthy controls using 16S rRNA gene and ITS1 sequencing. Compared with healthy individuals, asthma patients exhibited a significantly altered microbiota and increased bacterial and fungal alpha diversities in the airway. Microbial genera Moraxella, Capnocytophaga, and Ralstonia (bacteria) and Schizophyllum, Candida, and Phialemoniopsis (fungi) were more abundant in the asthma airways, while Rothia, Veillonella and Leptotrichia (bacteria) and Meyerozyma (fungus) were increased in healthy controls. The Moraxellaceae family and their genus Moraxella were significantly enriched in asthma patients compared with healthy controls (80.5-fold, P = 0.007 and 314.7-fold, P = 0.027, respectively). Moreover, Moraxellaceae, along with Schizophyllum, Candida, and Aspergillus (fungal genera), were positively associated with fungal alpha diversity. Correlation networks revealed 3 fungal genera (Schizophyllum, Candida, and Aspergillus) as important airway microbes in asthma that showed positive correlations with each other and multiple co-exclusions with other common microbiota. Moraxellaceae members were positively associated with asthma-enriched fungal taxa but negatively related to several healthyenriched bacterial taxa. Collectively, our findings revealed an altered microbiota and complex microbial interactions in the airways of asthma patients. The Moraxellaceae family and their genus Moraxella, along with 3 important fungal taxa, showed significant interactions with the airway microbiota, providing potential insights into the novel pathogenic mechanisms of asthma.

show abstract

Section: Introductionmentioning

confidence: 99%

The Interactions of Airway Bacterial and Fungal Communities in Clinically Stable Asthma

Liu

Liang

et al. 2020

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…These fractions were then tested on biofilms and filamentation of C. albicans that are important virulence factors for the candidiasis development. It is know that antifungal agents with the ability to modulate biofilm formation and suppress dimorphic switching can lead the homeostatic balance of oral microbiome, protecting the host from the pathogenicity of Candida species (Chanda et al, 2017). Interestingly, fractions SM-F1, and even more so, SM-F2 were capable of inhibiting both biofilm and filamentation.…”

Section: Discussionmentioning

confidence: 99%

Streptococcus mutans Secreted Products Inhibit Candida albicans Induced Oral Candidiasis

et al. 2020

View full text Add to dashboard Cite

In the oral cavity, Candida species form mixed biofilms with Streptococcus mutans, a pathogenic bacterium that can secrete quorum sensing molecules with antifungal activity. In this study, we extracted and fractioned culture filtrate of S. mutans, seeking antifungal agents capable of inhibiting the biofilms, filamentation, and candidiasis by Candida albicans. Active S. mutans UA159 supernatant filtrate components were extracted via liquid-liquid partition and fractionated on a C-18 silica column to resolve S. mutans fraction 1 (SM-F1) and fraction 2 (SM-F2). We found anti-biofilm activity for both SM-F1 and SM-F2 in a dose dependent manner and fungal growth was reduced by 2.59 and 5.98 log for SM-F1 and SM-F2, respectively. The SM-F1 and SM-F2 fractions were also capable of reducing C. albicans filamentation, however statistically significant differences were only observed for the SM-F2 (p = 0.004). SM-F2 efficacy to inhibit C. albicans was confirmed by its capacity to downregulate filamentation genes CPH1, EFG1, HWP1, and UME6. Using Galleria mellonella as an invertebrate infection model, therapeutic treatment with SM-F2 prolonged larvae survival. Examination of the antifungal capacity was extended to a murine model of oral candidiasis that exhibited a reduction in C. albicans colonization (CFU/mL) in the oral cavity when treated with SM-F1 (2.46 log) and SM-F2 (2.34 log) compared to the control (3.25 log). Although both SM-F1 and SM-F2 fractions decreased candidiasis in mice, only SM-F2 exhibited significant quantitative differences compared to the non-treated group for macroscopic lesions, hyphae invasion, tissue lesions, and inflammatory infiltrate. Taken together, these results indicate that the SM-F2 fraction contains antifungal components, providing a promising resource in the discovery of new inhibitors for oral candidiasis.

show abstract

“…Distinctive means and compounds may be used to prevent oral infections. Biomolecules produced by S. mutans, lactoferrin, and probiotics, applying chemicals and photodynamic therapy, can support the management of oral candidiasis [43].…”

Section: Compounds With Activity Against Oral Infectionsmentioning

confidence: 99%

Management of Streptococcus mutans-Candida spp. Oral Biofilms’ Infections: Paving the Way for Effective Clinical Interventions

Salehi

Kręgiel

Mahady

et al. 2020

JCM

View full text Add to dashboard Cite

Oral diseases are considered the most common noncommunicable diseases and are related to serious local and systemic disorders. Oral pathogens can grow and spread in the oral mucosae and frequently in biomaterials (e.g., dentures or prostheses) under polymicrobial biofilms, leading to several disorders such as dental caries and periodontal disease. Biofilms harbor a complex array of interacting microbes, increasingly unapproachable to antimicrobials and with dynamic processes key to disease pathogenicity, which partially explain the gradual loss of response towards conventional therapeutic regimens. New drugs (synthesized and natural) and other therapies that have revealed promising results for the treatment or control of these mixed biofilms are presented and discussed here. A structured search of bibliographic databases was applied to include recent research. There are several promising new approaches in the treatment of Candida spp.–Streptococcus mutans oral mixed biofilms that could be clinically applied in the near future. These findings confirm the importance of developing effective therapies for oral Candida–bacterial infections.

show abstract

The potential management of oral candidiasis using anti-biofilm therapies

Cited by 31 publications

References 44 publications

The Interactions of Airway Bacterial and Fungal Communities in Clinically Stable Asthma

The Interactions of Airway Bacterial and Fungal Communities in Clinically Stable Asthma

Streptococcus mutans Secreted Products Inhibit Candida albicans Induced Oral Candidiasis

Management of Streptococcus mutans-Candida spp. Oral Biofilms’ Infections: Paving the Way for Effective Clinical Interventions

Contact Info

Product

Resources

About